Clinical Trial Update: Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on an anti-CD19 CAR-T cell therapy being evaluated in Phase 1/Phase 2 for various leukemias and lymphoid cancers; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Lymphocytic Leukemia
• Lymphoblastic Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T cell therapy targeting CD19)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, B-Lymphocytic Leukemia, Chronic | Phase 1, Phase 2 | Status: RECRUITING